Analysis of Nektar’s Second Quarter Performance: Earnings Disappoint, Revenues Exceed Expectations
Nektar Therapeutics NKTR grappled with a loss per share of 25 cents in the second quarter of 2024, falling short of the Zacks Consensus Estimate of a loss of 21 cents. Stripping away the influence of non-cash restructuring and impairment charges, the enterprise disclosed an adjusted loss of 19 cents per share in the second ...










